Sexual & Reproductive Research research peptides

The short version

Aubrie Peptides is a reading desk, not a store. It collects what the published research literature actually says about two peptides that come up in conversations about reproductive hormones, libido, and sexual desire: kisspeptin and PT-141 (bremelanotide). A peptide is simply a short chain of amino acids — the same building blocks found in proteins, only smaller. These two have been studied because they act on the brain's reproductive circuitry in complementary ways: kisspeptin acts upstream, nudging the body's own hormonal thermostat (the hypothalamic-pituitary-gonadal axis), while PT-141 acts on melanocortin receptors involved in sexual motivation and desire.

This guide has one job: it tells you, in plain language and with citations, what each peptide was tested on, in which populations, and how far that evidence actually reaches. None of this is medical advice, and we never give a human dose. We cover the topic — including libido, arousal, and reproductive hormone function — frankly and with the detail the research deserves.

What this desk covers

The two peptides here approach the reproductive and sexual axis from different points of entry.

• Kisspeptin is the lead. It is a family of neuropeptides encoded by the KISS1 gene whose core job is to activate the body's own reproductive hormone cascade — driving GnRH release from the hypothalamus, which in turn drives LH and FSH from the pituitary, and then sex steroids from the gonads ^[7]. It is investigational, not approved for any indication, and is one of the central subjects of current fertility research. It has been studied in hypothalamic amenorrhea, IVF trigger protocols, and puberty onset ^[2][3][4].
• PT-141 takes a different path: it is a synthetic cyclic peptide that activates central melanocortin receptors (primarily MC4R) in the hypothalamus and limbic system, shifting sexual desire from the brain side of the equation ^[9]. It is the only compound on this desk with regulatory approval — cleared for acquired, generalized low sexual desire (HSDD) in premenopausal women — while all other uses remain off-label and investigational ^[12].

Together they illuminate how two distinct biological systems — the reproductive hormone axis and the central melanocortin system — converge on sexual health. Use the directory to read each one, or compare these peptides side by side.

Reproductive hormones & the fertility axis, plainly explained

The reproductive axis in both men and women runs on a pulse. The hypothalamus sends out bursts of GnRH (gonadotropin-releasing hormone), which tells the pituitary to release LH and FSH (the gonadotropins), which tell the gonads to produce sex steroids — testosterone, estrogen, progesterone. That pulse generator is what kisspeptin controls ^[7].

When kisspeptin binds its receptor (KISS1R, also called GPR54) on GnRH neurons, it fires them up — triggering the LH and FSH surge that drives reproductive function, puberty onset, ovulation, and gonadal steroid production ^[6][7]. Loss-of-function mutations in GPR54 cause failure of puberty and infertility in humans, which is the clearest proof that the kisspeptin-KISS1R system is not optional for reproductive life ^[7].

Sexual desire, by contrast, is a neurological event — and the melanocortin system, centered on MC4R in the hypothalamus and limbic structures, is one of the circuits that drives it ^[9]. PT-141 (bremelanotide) acts there: not on blood flow, not on hormones, but on the brain's motivation and reward wiring that generates the wanting of sex.

The two systems interact, but they are not the same system. Understanding both — and the honest state of evidence for each — is what this desk provides.

A note on how this desk reads the literature

Aubrie Peptides is a cross-referenced literature digest. Each peptide page synthesizes the peer-reviewed evidence for that compound, cites it by number, and links to a single shared references list that aggregates every source. Where evidence is thin, preliminary, or contested, we say so plainly — candor is part of the record, not a footnote to it.

We cover libido, arousal, and reproductive-hormone topics frankly, including the real-world reported effects people describe — clearly labeled "anecdotal, not clinical evidence" — alongside the study-attributed findings. We do not recommend, prescribe, or sell. The aim is an accurate map of what is known, so you can see where the science is solid and where it is still early.